In Alzheimer's disease (AD), early synaptic dysfunction is associated with the increased
oligomeric amyloid-beta peptide, which causes NMDAR-dependent synaptic depression …

The link between histopathological hallmarks of Alzheimer's disease (AD), ie amyloid
plaques, and neurofibrillary tangles, and AD-associated cognitive impairment, has long …

Drug development efforts that focused on single targets failed to provide effective treatment
for Alzheimer's disease (AD). Therefore, we designed cholinesterase inhibition (ChEI) …

Recent evidence suggests that soluble amyloid-β oligomers (AβOs) act as a key factor in the
pathogenetic mechanism of Alzheimer's disease (AD). AβOs induce neurotoxic and …

Synapse degeneration correlates strongly with cognitive impairments in Alzheimer's disease
(AD) patients. Soluble Amyloid‐beta (Aβ) oligomers are thought as the major trigger of …

Acute secondary neuronal cell death, as seen in neurodegenerative disease, cerebral
ischemia (stroke) and traumatic brain injury (TBI), drives spreading neurotoxicity into …

Alzheimer's disease (AD) is a leading cause of dementia in elderly individuals and
therapeutic options for AD are very limited. Over‐activation of N‐methyl‐D‐aspartate …

Alzheimer's disease (AD) is an age-related progressive neurodegenerative disease, and
early stage AD is characterized by synaptic dysfunction generally ascribed to soluble …

Sleep disturbance is a recognized risk factor for Alzheimer's disease (AD), but the
underlying micro-pathological evidence remains limited. To bridge this gap, we established …

The hippocampus and entorhinal cortex (EC) accumulate amyloid beta peptides (Aβ) that
promote neuropathology in Alzheimer's disease, but the early effects of Aβ on excitatory …